UBE2I Human

Ubiquitin-Conjugating Enzyme E2I Human Recombinant
Cat. No.
BT18417
Source
Escherichia Coli.
Synonyms
SUMO-conjugating enzyme UBC9, EC 6.3.2.-, SUMO-protein ligase, Ubiquitin-conjugating enzyme E2 I, Ubiquitin-protein ligase I, Ubiquitin carrier protein I, Ubiquitin carrier protein 9, p18, UBC9, C358B7.1.
Appearance
Sterile filtered colorless solution.
Purity

Greater than 95.0% as determined by Analysis by SDS-PAGE.

Usage
Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock
Quick Inquiry

Description

UBE2I Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 158 amino acids (1-158 aa)  & having a molecular mass of 18.0 kDa. UBE2I is purified by proprietary chromatographic techniques.

Product Specs

Introduction
Human Ubc9, a homologue of ubiquitin-conjugating enzymes (E2s), conjugates the ubiquitin homologue, small ubiquitin-like modifier 1 (SUMO-1), instead of ubiquitin. Demonstrating significant structural and functional similarity to yeast Ubc9, hUbc9 plays a role in the ubiquitin-dependent protein degradation system. This enzymatic pathway is responsible for the selective degradation of abnormal and short-lived proteins. The conjugation of ubiquitin relies on the activities of ubiquitin-activating (E1) and -conjugating (E2) enzymes.
Description
UBE2I Human Recombinant, produced in E.Coli, is a single, non-glycosylated polypeptide chain consisting of 158 amino acids (1-158 aa). With a molecular mass of 18.0 kDa, UBE2I is purified using proprietary chromatographic techniques.
Physical Appearance
Sterile filtered colorless solution.
Formulation
UBE2I (1mg/ml) is supplied in a solution containing 50mM HEPES (pH 7.4), 150mM NaCl, 1mM DTT, and 10% glycerol.
Stability
For short-term storage (2-4 weeks), store at 4°C. For extended periods, store frozen at -20°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Avoid repeated freeze-thaw cycles.
Purity
Purity is greater than 95.0% as determined by SDS-PAGE analysis.
Synonyms
SUMO-conjugating enzyme UBC9, EC 6.3.2.-, SUMO-protein ligase, Ubiquitin-conjugating enzyme E2 I, Ubiquitin-protein ligase I, Ubiquitin carrier protein I, Ubiquitin carrier protein 9, p18, UBC9, C358B7.1.
Source
Escherichia Coli.
Amino Acid Sequence
MSGIALSRLA QERKAWRKDH PFGFVAVPTK NPDGTMNLMN WECAIPGKKG TPWEGGLFKL RMLFKDDYPS SPPKCKFEPP LFHPNVYPSG TVCLSILEED KDWRPAITIK QILLGIQELL NEPNIQDPAQ AEAYTIYCQN RVEYEKRVRA QAKKFAPS.

Product Science Overview

Introduction

Ubiquitin-Conjugating Enzyme E2I, also known as UBC9, is a crucial enzyme in the ubiquitin-proteasome pathway (UPP). This pathway is essential for the post-translational regulation of protein expression, impacting nearly all life activities in eukaryotes. UBC9 is a member of the E2 enzyme family and plays a significant role in the conjugation of Small Ubiquitin-like Modifier (SUMO) to various target proteins .

Discovery and Structure

The UBC9 gene was first identified in 1996 by Watanabe et al. It contains an open reading frame of 474 nucleotides encoding 158 amino acids . The enzyme is involved in the SUMOylation process, which is analogous to ubiquitination but uses SUMO proteins instead of ubiquitin .

Function and Mechanism

UBE2I is responsible for transferring activated SUMO from the E1 activating enzyme to the substrate proteins. This process involves a complex three-step enzyme cascade:

  1. Activation: The E1 enzyme activates SUMO using ATP.
  2. Conjugation: The activated SUMO is transferred to UBE2I.
  3. Ligation: The E3 ligase enzyme facilitates the transfer of SUMO from UBE2I to the target protein .

This SUMOylation process regulates various cellular processes, including protein turnover, stress response, cell cycle, organelle synthesis, and maintenance of intracellular homeostasis .

Biological Significance

UBE2I plays a pivotal role in numerous cellular functions and is implicated in various diseases. Dysregulation of UBE2I has been linked to the development of several human disorders, including systemic inflammation, cancer, and neurodegenerative diseases . For instance, UBE2I is upregulated in hepatocellular carcinoma (HCC) and is associated with cancer progression and poor prognosis .

Research and Applications

Research on UBE2I has revealed its potential as a therapeutic target and biomarker in cancer treatment. Functional experiments have shown that knockdown of UBE2I significantly inhibits the migration and invasion of HCC cells . Additionally, UBE2I’s involvement in the regulatory network of key genes linked to poor prognosis in HCC highlights its importance in cancer biology .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

Related Products

UBE2A Human
Ubiquitin Conjugating Enzyme E2A Human Recombinant
Cat. No.
BT17238
Source
Escherichia Coli.
UBE2B Human
Ubiquitin Conjugating Enzyme E2B Human Recombinant
Cat. No.
BT17335
Source
Escherichia Coli.
UBE2D1 Human
Ubiquitin Conjugating Enzyme E2D1 Human Recombinant
Cat. No.
BT17507
Source
Escherichia Coli.
UBE2H Human
Ubiquitin-Conjugating Enzyme E2H Human Recombinant
Cat. No.
BT18332
Source
Escherichia Coli.
THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.